Unnoticed Overhauls: Dividends, Succession and Bitcoin Surges Among Hong Kong's Under-the-Radar Stocks

Hong Kong's under-the-radar equities are quietly undergoing a wave of structural overhauls and dividend payouts. I'm told that as capital seeks new narratives across the market, everything from crypto ETFs to traditional pharmaceuticals is seeing an unexpected burst of activity this month. Later this year, we will likely see the full impact of these stealthy successions and financial re-engineerings that took place just ahead of the 2026 interim reporting season.

FA Southern Bitcoin (3066.HK)

Riding the wave of Hong Kong's Web3.0 policy push, FA Southern Bitcoin (3066.HK) has been a standout performer recently. According to people familiar with the matter, this CME Bitcoin futures-tracking ETF surged over 130% in 2023 and easily topped a 50% return in the early months of 2024. As market enthusiasm persists, the ticker has outperformed the broader index this year.

Pak Fah Yeow (0239.HK)

Pak Fah Yeow (0239.HK), a traditional healthcare brand with a 95-year history, is undergoing a major generational shift at the top. I've learned that as part of a family succession plan, controlling shareholder Hexagan completed a share transfer at the end of June 2026, handing over control to the founders' children. With total revenue sitting at HKD 213.9M for 2025, this marks a major structural overhaul for the company and could pave the way for further internal restructuring.

Kanghua Healthcare (3689.HK)

This Dongguan-based hospital operator just delivered a staggering profitability report. I'm told that Kanghua Healthcare (3689.HK) saw its net profit skyrocket over 800% to RMB 94.5M in 2025, despite a slight 1.5% dip in revenue. The company is set to distribute a final dividend of RMB 0.16 per share by the end of July 2026. A recent independent board appointment also signals an ongoing cleanup of its corporate governance.

Shandong Xinhua Pharmaceutical (0719.HK)

Shandong Xinhua Pharmaceutical (0719.HK) is moving fast on both the R&D and shareholder return fronts. Not only is the drugmaker paying out its final dividend in late July 2026, but it also achieved first-patient enrollment in China for its Phase II OAB-14 trials. Alongside the launch of a Phase I trial for an innovative pulmonary arterial hypertension drug, these pipeline milestones serve as significant catalysts before the next earnings cycle.

Sunshine Oilsands (2012.HK)

The financing saga at Sunshine Oilsands (2012.HK) took another twist recently. In late July, the company pushed the deadline for a 114M-share placement all the way to the end of 2026. However, according to people familiar with the matter, the company's recent joint venture with Shanghai Yinsheng to explore geothermal energy suggests this traditional oil sands player is quietly hunting for a green transition exit.

Also

• iShares Hang Seng TECH ETF (9067.HK): Boosted by global capital rebalancing, this tech-tracking ETF has rallied recently alongside major internet peers. Market watchers are closely monitoring fund flows as the AI hardware bubble shows signs of loosening.
• Most Kwai Chung (1716.HK): The media services provider flipped to a profit in FY2025, with revenue surging roughly 70% to HKD 93.6M. Its recent acquisition of To Be Honest Limited makes it a space to watch for integration updates.
• LEGION CONSO (2129.HK): This Singaporean logistics firm swung to a SGD 5.1M loss in FY2025 amid rising costs, but I'm told it is still aggressively expanding its fleet capacity with new prime mover purchases.
• NagaCorp (3918.HK) & Yuanda China (2789.HK): Both companies have been flying under the radar recently. NagaCorp continues its routine casino-hotel operations, while curtain wall builder Yuanda China remains quiet with no immediate catalysts.

This article does not constitute investment advice.